-
Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
Zhu Y, Mooney LF, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser Y. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug and Alcohol Dependence 2021;228:108996.
-
Concomitant cannabis misuse and associations with depression, pain and substance misuse among patients prescribed opioids.
Bryan MA, Charron E, Adeoye-Olatunde O, Brown J, Ghitza UE, Winhusen TJ, Cochran G. Concomitant cannabis misuse and associations with depression, pain and substance misuse among patients prescribed opioids. Pharmacy 2021;9:134.
-
Racial/ethnic equity in substance use treatment research: The way forward [commentary].
Burlew AK, McCuistian C, Szapocznik J. Racial/ethnic equity in substance use treatment research: The way forward [commentary]. Addiction Science & Clinical Practice 2021;16:50.
-
Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes.
Luderer HF, Campbell ANC, Nunes EV, Enman NM, Xiong X, Gerwien R, Maricich YA. Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes. Journal of Substance Abuse Treatment 2021;132:108585.
-
Prevalence of medical cannabis use and associated health conditions documented in electronic health records among primary care patients in Washington State.
Matson TE, Carrell DS, Bobb JF, Cronkite DJ, Oliver MM, Luce C, Ghitza UE, Hsu CW, Campbell CI, Browne KC, Binswanger IA, Saxon AJ, Bradley KA, Lapham GT. Prevalence of medical cannabis use and associated health conditions documented in electronic health records among primary care patients in Washington State. JAMA Network Open 2021;4(5):e219375.
-
Validating the clinical relevance of alternative stimulant use treatment outcome measures by examining their association with 3-month follow-up outcomes.
Miguel AQC, Smith CL, Burduli E, Roll JM, McPherson SM. Validating the clinical relevance of alternative stimulant use treatment outcome measures by examining their association with 3-month follow-up outcomes. Experimental and Clinical Psychopharmacology 2021;29(3):288-293.
-
An examination of the feasibility of detecting cocaine use using smartwatches.
Ertin E, Sugavanam N, Holtyn AF, Preston KL, Bertz JW, Marsch LA, McLeman B, Shmueli-Blumberg D, Collins J, King JS, McCormack J, Ghitza UE. An examination of the feasibility of detecting cocaine use using smartwatches. Frontiers in Psychiatry 2021;12:674691.
-
Race, psychosocial characteristics, and treatment outcomes among individuals undergoing treatment for cannabis use disorder: A latent profile analysis based on preferred method of using cannabis.
Ullrich HS, Torbati A, Fan W, Arbona C, Cano MA, Essa S, Harvey L, Vaughan EL, de Dios MA. Race, psychosocial characteristics, and treatment outcomes among individuals undergoing treatment for cannabis use disorder: A latent profile analysis based on preferred method of using cannabis. Journal of Substance Abuse Treatment 2021;131:108561.
-
High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder.
Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X, Dziura J, Hawk KF, McCormack R, Saxon AJ, D'Onofrio G. High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Network Open 2021; 4(7):e2117128.
-
Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser Y, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction 2021;117:151-161.